Skip to content

Study · Animal study (in vivo) · mouse · 2002

3 results

Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation.

Giron S, Tejera AM, Ripoll GV, Gomez DE, Alonso DF

Journal of surgical oncology1 Sept 2002Cited by 30 (Europe PMC)

PMID12210026 (opens in a new tab)DOI10.1002/jso.10141 (opens in a new tab)PepBankPUB-12210026
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In manipulated tumor-bearing mice, lymph node involvement was 12% with DDAVP versus 87% without treatment (P < 0.02).

    In plain wordsIn mice with manipulated tumors, lymph node involvement was lower with DDAVP than without treatment.

    Peptide
    Desmopressin
    Outcome
    DecreaseLymph node involvement
    Study

    mousen: not reported in source

    BALB/c mice bearing F3II mammary carcinoma
    Comparator
    No treatment
    Outcome group
    Tumor growth · Cancer
    Studied dose
    2 microg/kg · intravenousAs given in this study (mouse).

    Source sentences

    Summary
    The incidence of lymph node involvement in manipulated animals was 12% with DDAVP and 87% without treatment (P < 0.02).
    2 context sentences
    Summary · context
    Female BALB/c mice bearing the highly aggressive F3II mammary carcinoma were subjected to repeated manipulations of primary tumors (0.5 kg/cm(2) during 2 min), followed (or not) by surgical excision.
    Summary · context
    DDAVP was administered intravenously 30 min before and 24 h after each manipulation or surgery, at a dose of 2 microg/kg.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In DDAVP-treated tumor-bearing mice, axillary nodes showed sinusal histiocytosis and no cancer cells.

    In plain wordsIn DDAVP-treated mice, axillary nodes showed sinusal histiocytosis and no cancer cells.

    Peptide
    Desmopressin
    Outcome
    Not applicableAxillary node histology
    Study

    mousen: not reported in source

    BALB/c mice bearing F3II mammary carcinoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    2 microg/kg · intravenousAs given in this study (mouse).

    Source sentences

    Summary
    Histopathological analysis of axillary nodes from DDAVP-treated animals showed sinusal histiocytosis and no evidence of cancer cells.
    2 context sentences
    Summary · context
    Female BALB/c mice bearing the highly aggressive F3II mammary carcinoma were subjected to repeated manipulations of primary tumors (0.5 kg/cm(2) during 2 min), followed (or not) by surgical excision.
    Summary · context
    DDAVP was administered intravenously 30 min before and 24 h after each manipulation or surgery, at a dose of 2 microg/kg.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In tumor-bearing mice, DDAVP reduced metastatic lung nodules by about 65% (P = 0.026).

    In plain wordsIn mice with mammary tumors, DDAVP reduced metastatic lung nodules by about 65%.

    Peptide
    Desmopressin
    Outcome
    DecreaseMetastatic lung nodules
    Study

    mousen: not reported in source

    BALB/c mice bearing F3II mammary carcinoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    2 microg/kg · intravenousAs given in this study (mouse).

    Source sentences

    Summary
    Metastatic lung nodules were also reduced about 65% in animals treated with DDAVP (P = 0.026).
    2 context sentences
    Summary · context
    Female BALB/c mice bearing the highly aggressive F3II mammary carcinoma were subjected to repeated manipulations of primary tumors (0.5 kg/cm(2) during 2 min), followed (or not) by surgical excision.
    Summary · context
    DDAVP was administered intravenously 30 min before and 24 h after each manipulation or surgery, at a dose of 2 microg/kg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.